On the basis of the data we have reported and in a translational perspective, NRP-1-interfering molecules, such as nanobodies or small molecules interacting with the extracellular domain [47], might be used in combined therapeutic regimens for HNSCC. The gene discussed is NRP1; the disease is head and neck squamous cell carcinoma.